Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotie To Combine With Synosia To Form A "Global Leader" In CNS Drug Development

This article was originally published in The Pink Sheet Daily

Executive Summary

A Phase III drug for alcohol dependence and two Parkinson's disease therapies will head the pipeline of a proposed new European CNS drug development company.
Advertisement

Related Content

Biotie Therapies’ Options Expand On Nalmefene And Tozadenant Progress
Roche Enters Hearing-Loss Space In Risk-Sharing Venture With Inception, Versant
Biotie Buys Newron In Pain Deal; Price Brings Little Relief
Biotie Buys Newron In Pain Deal; Price Brings Little Relief
UCB Provides Synosia With Its First Out-Licensing Deal And Leads Its $30M Series C Funding

Topics

Advertisement
UsernamePublicRestriction

Register

PS071678

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel